Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine（2023）

引用 0|浏览2

暂无评分

摘要

There have been unprecedented strides in theranostics, facilitating the bidirectional “see and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate-specific membrane antigen (PSMA)–targeted, β-emitter 177Lu–labeled radioligand therapy (RLT) as a viable

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要